$CNO

CNO Financial Group, Inc. (CNO): Results of Operations and Financial Condition

CNO Financial Group, Inc. (CNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. News For Immediate Release CNO Financial Group Reports Second Quarter 2026 Results Carmel, Ind., July 30, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results: • Strong execution and momentum continues; Raising 2026 operating earni

Original reporting
Published Jul 30, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CNO
Neutral
medium confidence
Mentioned
$CNO
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

This disclosure updates CNO’s quarterly financial trajectory, including net income, insurance product margins, investment income and losses, and balance sheet composition (investments, liabilities, equity). Traders can use it to reassess earnings power and investment-related volatility assumptions.

02

Market read

Provides fresh quarterly financial statement detail that may influence near-term positioning, but the excerpt does not show a standalone guidance change or major corporate event.

03

What to watch

Traders may instead focus on the direction of net realized investment losses, embedded derivative and market risk benefit fair value changes, and changes in deferred acquisition costs or reinsurance receivables.

Relevance 7/10Novelty 4/10Timing: filed after market close on 2026-07-30
alphai · Earnings readCNO · 2Q 2026 · ended Jun-26

2Q 2026 total revenues were $ 1,285.2 million and net income was $ 125.9 million, while net operating income was $ 119.5 million.

Solid quarter

Total revenues, net income, net operating income, insurance product margin, and each reported annuity, health, and life margin were higher than their respective 1Q 2026 and 2Q 2025 tabulated amounts.

Revenue
$ 1,285.2 million
Annuity
$ 10.2 million
EPS · non-GAAP
$ 1.26

Key metrics

as reported
MetricValueq/qy/y
Insurance policy incomeGAAP$ 680.7 million
Net investment income: General account assetsGAAP$ 411.9 million
Net investment income: Policyholder and other special-purpose portfoliosGAAP$ 185.1 million
Realized investment lossesGAAP$ (8.6) million
Other investment lossesGAAP$ (6.1) million
Total investment lossesGAAP$ (14.7) million
Fee revenue and other incomeGAAP$ 22.2 million
Total revenuesGAAP$ 1,285.2 million
Insurance policy benefitsGAAP$ 742.5 million
Liability for future policy benefits remeasurement gainGAAP$ (15.3) million
Change in fair value of market risk benefitsGAAP$ (8.3) million
Interest expenseGAAP$ 55.3 million
Amortization of deferred acquisition costs and present value of future profitsGAAP$ 74.9 million
Other operating costs and expensesGAAP$ 276.4 million
Total benefits and expensesGAAP$ 1,125.5 million
Income before income taxesGAAP$ 159.7 million
Income tax expenseGAAP$ 33.8 million
Net incomeGAAP$ 125.9 million
Net income per diluted shareGAAP$ 1.33
Total insurance product marginother$ 279.0 million
Income from insurance productsother$ 126.1 million
Operating earnings before taxesother$ 151.0 million
Net operating incomenon-GAAP$ 119.5 million
Net operating income per diluted sharenon-GAAP$ 1.26
Net non-operating incomeother$ 6.4 million
Net non-operating income per diluted shareother$ 0.07
Book value per common shareother$ 27.96
Book value per common share, excluding accumulated other comprehensive lossother$ 40.72
Book value per diluted share, excluding accumulated other comprehensive lossother$ 39.92

Segments

SegmentRevenueq/qy/y
AnnuityInsurance policy income was $ 10.2 million, net investment income was $ 163.9 million, interest credited was $ (75.7) million, and annuity margin was $ 60.6 million.$ 10.2 million
HealthInsurance policy income was $ 436.4 million, net investment income was $ 75.8 million, insurance policy benefits were $ (322.3) million, and health margin was $ 147.2 million.$ 436.4 million
LifeInsurance policy income was $ 234.1 million, net investment income was $ 38.4 million, insurance policy benefits were $ (139.3) million, and life margin was $ 71.2 million.$ 234.1 million

What drove it

  • Total insurance product margin was $ 279.0 million, comprising annuity margin of $ 60.6 million, health margin of $ 147.2 million, and life margin of $ 71.2 million.
  • Policyholder and other special-purpose portfolios net investment income was $ 185.1 million.
  • General account assets net investment income was $ 411.9 million.
  • Net non-operating income was $ 6.4 million, including $ 34.6 million of changes in fair value of embedded derivative liabilities and market risk benefits.

Concerns

  • Insurance policy benefits were $ 742.5 million, compared with $ 576.6 million in 1Q 2026 and $ 658.4 million in 2Q 2025.
  • Fee revenue and other income was $ 22.2 million, compared with $ 48.8 million in 1Q 2026 and $ 34.9 million in 2Q 2025.
  • Expenses related to TechMod initiative were $ (9.7) million.
  • Realized investment losses were $ (8.6) million and other investment losses were $ (6.1) million.

What to watch

  • Health margin was $ 147.2 million and insurance policy benefits in Health were $ (322.3) million.
  • Policyholder account balances were $ 19,640.9 million at Jun-26.
  • Fixed indexed annuities average net insurance liabilities were $ 11,316.3 million and margin/average net insurance liabilities was 1.74 %.
  • Investment borrowings were $ 2,941.7 million at Jun-26.

Balance sheet and cash flow

  • Total investments were $ 30,742.9 million at Jun-26.
  • Cash and cash equivalents - unrestricted were $ 1,289.7 million at Jun-26.
  • Total assets were $ 39,861.2 million at Jun-26.
  • Investment borrowings were $ 2,941.7 million at Jun-26.
  • Borrowings related to variable interest entities were $ 274.5 million at Jun-26.
  • Notes payable - direct corporate obligations were $ 1,336.3 million at Jun-26.
  • Total liabilities were $ 37,269.6 million at Jun-26.
  • Total shareholders' equity was $ 2,591.6 million at Jun-26.

Analysis

CNO reported 2Q 2026 total revenues of $ 1,285.2 million, compared with $ 1,029.6 million in 1Q 2026 and $ 1,151.5 million in 2Q 2025. Net income was $ 125.9 million and net income per diluted share was $ 1.33, versus $ 37.7 million and $ 0.39 in 1Q 2026 and $ 91.8 million and $ 0.91 in 2Q 2025. Net operating income was $ 119.5 million, or $ 1.26 per diluted share, compared with $ 101.3 million, or $ 1.05 per diluted share, in 1Q 2026.

Insurance product margin was $ 279.0 million, compared with $ 256.9 million in 1Q 2026 and $ 252.4 million in 2Q 2025. Health margin was $ 147.2 million, life margin was $ 71.2 million, and annuity margin was $ 60.6 million. Health insurance policy income was $ 436.4 million and health insurance policy benefits were $ (322.3) million. Life insurance policy income was $ 234.1 million, while annuity net investment income was $ 163.9 million.

The revenue mix included $ 411.9 million of general account assets net investment income and $ 185.1 million of policyholder and other special-purpose portfolios net investment income. Fee revenue and other income was $ 22.2 million. Benefits and expenses totaled $ 1,125.5 million, including $ 742.5 million of insurance policy benefits, $ 74.9 million of amortization of deferred acquisition costs and present value of future profits, and $ 276.4 million of other operating costs and expenses.

Non-operating items moved to net non-operating income of $ 6.4 million from net non-operating loss of $ (63.6) million in 1Q 2026. The 2Q 2026 figure included $ 34.6 million of changes in fair value of embedded derivative liabilities and market risk benefits, partially offset by $ (13.6) million of net realized investment losses from disposals, impairments and change in allowance for credit losses and $ (9.7) million of expenses related to TechMod initiative.

At Jun-26, total investments were $ 30,742.9 million, unrestricted cash and cash equivalents were $ 1,289.7 million, and total shareholders' equity was $ 2,591.6 million. Investment borrowings were $ 2,941.7 million and notes payable - direct corporate obligations were $ 1,336.3 million. The supplied filing text contains no forward guidance or capital-return disclosure.

Not in the filing

stated, not guessed
  • Forward guidance
  • Prior-release outlook and guidance comparison
  • Gross margin
  • Operating cash flow
  • Free cash flow
  • Share repurchases
  • Dividends
  • Named executive commentary and executive quotes
  • Tax rate
  • Complete financial supplement pages after the truncated filing text, including the remainder of the Margin from Annuity Products table and subsequent sections

AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The SEC 8-K (Item 2.02) attaches a quarterly financial supplement for 2Q2026, with consolidated balance sheet, statement of operations, and financial summary tables.

Company-level read

Ticker impact

$CNONeutralMedium confidence
Context

CNO filed an 8-K with its 2Q2026 results supplement, including consolidated balance sheet and income statement figures for 2026 quarters.

Expected impact

Likely modest, unless traders focus on a specific line item trend (investment losses, embedded derivative impacts, or margin changes) versus prior quarters.

Evidence & confidence

The text includes detailed quarterly financial statement line items for 2025 and 2026, but it does not provide explicit guidance, deal terms, or a clear single surprise datapoint in the excerpt.

Market effects

Life insurers can see sentiment tied to investment income volatility and reserve-related items; this update may affect sector read-through modestly.

Primarily US-focused given the issuer and SEC filing.

Limited, unless investment portfolio moves signal broader credit or rates stress.

Counterpoint

Without explicit guidance or a clearly highlighted surprise metric in the excerpt, the market may treat this as routine quarterly disclosure rather than a catalyst.

Key entities

  • CNO Financial Group, Inc.

    US life insurer and filer of the 8-K with 2Q2026 results supplement.

Every CNO earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$CNOMed

California Nanotechnologies Posts 28% Revenue Growth in Q1 FY2027 as Nuclear Pivot Takes Hold

California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.

$CNOHighAI 9/10

CNO Financial (CNO) Q2 2026 Earnings Call Transcript

CNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.

$CNOMed

CNO Financial posts insurance income gain on 16-quarter sales streak

CNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.

$CNOMed

CNO Financial Group’s (NYSE:CNO) Q2 CY2026 Sales Beat Estimates

Insurance services company CNO Financial Group (NYSE: CNO) announced better-than-expected revenue in Q2 CY2026, with sales up 34.6% year on year to $1.29 billion. Its GAAP profit of $1.33 per share was 36.4% above analysts’ consensus estimates. Is now the time to buy CNO Financial Group? Find out by accessing our full research report, it’s free.

$BYNDMed

Why Beyond Meat Stock Slumped Last Month

Beyond Meat (BYND) shares fell 22% in August despite beating Q2 earnings expectations. Revenue declined 8% YoY to $68.8M, but GAAP net profit turned positive due to a one-time accounting gain. The company also executed a 1-to-30 reverse stock split to meet Nasdaq listing requirements.